Briefing17 October 2026·7 min read
Drug licensing deals involving China-based companies, 19 August – 14 October 2026
22 signed deals in eight weeks, worth about US$24 billion in total potential value. Most of that depends on future milestones, and at least 8 of the 10 largest deals cover medicines not yet tested in patients.